866-997-4948(US-Canada Toll Free)

Hepcidin (Liver Expressed Antimicrobial Peptide 1 or Putative Liver Tumor Regressor or HAMP) - Pipeline Review, H2 2017

Published By :

Global Markets Direct

Published Date : Oct 2017

Category :

Pharmaceutical

No. of Pages : 38 Pages

Hepcidin (Liver Expressed Antimicrobial Peptide 1 or Putative Liver Tumor Regressor or HAMP) - Pipeline Review, H2 2017

Summary

According to the recently published report 'Hepcidin - Pipeline Review, H2 2017'; Hepcidin (Liver Expressed Antimicrobial Peptide 1 or Putative Liver Tumor Regressor or HAMP) pipeline Target constitutes close to 5 molecules. Out of which approximately 5 molecules are developed by Companies.

Hepcidin (Liver Expressed Antimicrobial Peptide 1 or Putative Liver Tumor Regressor or HAMP) - Hepcidin is a protein encoded by the HAMP gene. It acts by promoting endocytosis and degradation of ferroportin leading to the retention of iron in iron exporting cells and decreased flow of iron into plasma. It controls the major flows of iron into plasma, absorption of dietary iron in the intestine and recycling of iron by macrophages.

The report 'Hepcidin - Pipeline Review, H2 2017' outlays comprehensive information on the Hepcidin (Liver Expressed Antimicrobial Peptide 1 or Putative Liver Tumor Regressor or HAMP) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Hepcidin (Liver Expressed Antimicrobial Peptide 1 or Putative Liver Tumor Regressor or HAMP) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 2 and 1 respectively. Report covers products from therapy areas Hematological Disorders, Genetic Disorders, Immunology and Oncology which include indications Hemochromatosis, Thalassemia, Acute Inflammation, Anemia, Anemia in Chronic Kidney Disease (Renal Anemia), Iron Deficiency Anemia, Polycythemia Vera and Sickle Cell Disease.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Hepcidin (Liver Expressed Antimicrobial Peptide 1 or Putative Liver Tumor Regressor or HAMP)
- The report reviews Hepcidin (Liver Expressed Antimicrobial Peptide 1 or Putative Liver Tumor Regressor or HAMP) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Hepcidin (Liver Expressed Antimicrobial Peptide 1 or Putative Liver Tumor Regressor or HAMP) targeted therapeutics and enlists all their major and minor projects
- The report assesses Hepcidin (Liver Expressed Antimicrobial Peptide 1 or Putative Liver Tumor Regressor or HAMP) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Hepcidin (Liver Expressed Antimicrobial Peptide 1 or Putative Liver Tumor Regressor or HAMP) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Hepcidin (Liver Expressed Antimicrobial Peptide 1 or Putative Liver Tumor Regressor or HAMP)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Hepcidin (Liver Expressed Antimicrobial Peptide 1 or Putative Liver Tumor Regressor or HAMP) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Hepcidin (Liver Expressed Antimicrobial Peptide 1 or Putative Liver Tumor Regressor or HAMP) - Overview 6
Hepcidin (Liver Expressed Antimicrobial Peptide 1 or Putative Liver Tumor Regressor or HAMP) - Therapeutics Development 7
Products under Development by Stage of Development 7
Products under Development by Therapy Area 8
Products under Development by Indication 9
Products under Development by Companies 10
Hepcidin (Liver Expressed Antimicrobial Peptide 1 or Putative Liver Tumor Regressor or HAMP) - Therapeutics Assessment 12
Assessment by Mechanism of Action 12
Assessment by Route of Administration 14
Assessment by Molecule Type 16
Hepcidin (Liver Expressed Antimicrobial Peptide 1 or Putative Liver Tumor Regressor or HAMP) - Companies Involved in Therapeutics Development 18
Daiichi Sankyo Co Ltd 18
Pieris Pharmaceuticals Inc 18
Protagonist Therapeutics Inc 19
Hepcidin (Liver Expressed Antimicrobial Peptide 1 or Putative Liver Tumor Regressor or HAMP) - Drug Profiles 20
DS-79182026 - Drug Profile 20
Product Description 20
Mechanism Of Action 20
R&D Progress 20
Fusion Protein to Replace Hepcidin for Iron Overload Disorders - Drug Profile 21
Product Description 21
Mechanism Of Action 21
R&D Progress 21
M-009 - Drug Profile 22
Product Description 22
Mechanism Of Action 22
R&D Progress 22
PRS-080 - Drug Profile 23
Product Description 23
Mechanism Of Action 23
R&D Progress 23
PTG-300 - Drug Profile 26
Product Description 26
Mechanism Of Action 26
R&D Progress 26
Hepcidin (Liver Expressed Antimicrobial Peptide 1 or Putative Liver Tumor Regressor or HAMP) - Dormant Products 28
Hepcidin (Liver Expressed Antimicrobial Peptide 1 or Putative Liver Tumor Regressor or HAMP) - Discontinued Products 29
Hepcidin (Liver Expressed Antimicrobial Peptide 1 or Putative Liver Tumor Regressor or HAMP) - Product Development Milestones 30
Featured News & Press Releases 30
Sep 20, 2017: Protagonist Therapeutics Announces Preliminary Phase 1 Study Results with Novel Hepcidin Mimetic, PTG-300 30
Jun 04, 2017: Pieris Pharmaceuticals Announces Presentation of Clinical Data for Anemia Drug Candidate, PRS-080, at the 54th ERA-EDTA Congress 30
May 25, 2017: Protagonist Therapeutics Initiates Phase 1 Study with Novel Hepcidin Mimetic, PTG-300 31
Jul 28, 2016: Protagonist Therapeutics Receives SBIR Funding for the Development of Injectable Hepcidin Mimetics for Treatment of Iron Overload Disorders 31
May 06, 2016: Drug-like Compound Shows Promise in Treating Two Blood Diseases 32
Dec 07, 2015: Pieris Pharmaceuticals Presents Clinical Data for its Hepcidin Antagonist Program, PRS-080, at the 2015 American Society Of Hematology Annual Meeting 33
Nov 05, 2015: Pieris Pharmaceuticals Announces Presentation Of Clinical Data For Its Hepcidin Antagonist Program, Prs-080, At The 2015 American Society Of Hematology Annual Meeting 33
Jun 10, 2015: Pieris Pharmaceuticals Completes Dosing of Healthy Volunteers in Phase I Clinical Trial for Anticalin Program in Anemia 34
Dec 11, 2014: Pieris Initiates Phase I Clinical Trial for Anticalin to Treat Anemia 35
Dec 13, 2011: Pieris Presents Preclinical Data For PRS-080 Hepcidin Antagonist Anticalin Program At ASH Annual Meeting 35
May 23, 2011: Pieris Announces Preclinical In Vitro And In Vivo Data For Anticalin PRS-080 Hepcidin Antagonist Drug Program 36
Appendix 37
Methodology 37
Coverage 37
Secondary Research 37
Primary Research 37
Expert Panel Validation 37
Contact Us 37
Disclaimer 38

List of Tables
Number of Products under Development by Stage of Development, H2 2017 7
Number of Products under Development by Therapy Areas, H2 2017 8
Number of Products under Development by Indication, H2 2017 9
Number of Products under Development by Companies, H2 2017 10
Products under Development by Companies, H2 2017 11
Number of Products by Stage and Mechanism of Actions, H2 2017 13
Number of Products by Stage and Route of Administration, H2 2017 15
Number of Products by Stage and Molecule Type, H2 2017 17
Pipeline by Daiichi Sankyo Co Ltd, H2 2017 18
Pipeline by Pieris Pharmaceuticals Inc, H2 2017 19
Pipeline by Protagonist Therapeutics Inc, H2 2017 19
Dormant Projects, H2 2017 28
Discontinued Products, H2 2017 29

List of Figures
Number of Products under Development by Stage of Development, H2 2017 7
Number of Products under Development by Therapy Areas, H2 2017 8
Number of Products under Development by Top 10 Indications, H2 2017 9
Number of Products by Mechanism of Actions, H2 2017 12
Number of Products by Stage and Mechanism of Actions, H2 2017 12
Number of Products by Routes of Administration, H2 2017 14
Number of Products by Stage and Routes of Administration, H2 2017 14
Number of Products by Molecule Types, H2 2017 16
Number of Products by Stage and Molecule Types, H2 2017 16

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title
  • Company
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *